Podocyte pathology and nephropathy - sphingolipids in glomerular diseases

Frontiers in Endocrinology

Volumn 5, Issue JUL, 2014, Pages

  Merscher, Sandra ^a   Fornoni, Alessia ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ASMase; Ceramide; Glomerular disease; Kidney disease; Podocyte; S1P; SMPDL3b; Sphingolipid

Indexed keywords

ALPHA GALACTOSIDASE; BETA GLUCOSIDASE; BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; CERAMIDE; G PROTEIN COUPLED RECEPTOR; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; PHOSPHOETHANOLAMINE; PLATELET DERIVED GROWTH FACTOR; PUROMYCIN AMINONUCLEOSIDE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN LIKE PHOSPHODIESTERASE 3B; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE 2 EPIMERASE;

ACTIN FILAMENT; DIABETIC NEPHROPATHY; ENDOPLASMIC RETICULUM; ENDOSOME; FABRY DISEASE; FOCAL GLOMERULOSCLEROSIS; GAUCHER DISEASE; GLOMERULAR FILTRATION BARRIER; GLOMERULOPATHY; HIV ASSOCIATED NEPHROPATHY; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; LIPID METABOLISM; LIPID RAFT; LIPID STORAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYSOSOME; NEPHROTIC SYNDROME; NIEMANN PICK DISEASE; NONHUMAN; PATHOLOGY; PODOCYTE; PROTEINURIA; REVIEW; SANDHOFF DISEASE; SIGNAL TRANSDUCTION; SPHINGOLIPID ACCUMULATION; SPHINGOLIPID METABOLISM; TAY SACHS DISEASE; XENOTRANSPLANTATION;

EID: 84905378568     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00127     Document Type: Review

References (139)

1. McIlwain H. The second thudichum lecture. Cerebral isolates and neurochemical discovery. Biochem Soc Trans (1975) 3:579-90.
2. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev (2003) 83:253-307. doi: 10.1152/physrev.00020.2002
3. Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet (2000) 24:333-5. doi:10.1038/71724
4. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol (2007) 17:428-37. doi:10.1016/j.tcb.2007.06.006
5. Kestilä M, Lenkkeri U, Männikkö M, Lamerdin J, McCready P, Putaala H, et al. Positionally cloned gene for a novel glomerular protein - nephrin - is mutated in congenital nephrotic syndrome. Mol Cell (1998) 1:575-82. doi:10.1016/S1097-2765(00)80057-X
6. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet (2000) 24:349-54. doi:10.1038/74166
7. Li C, Ruotsalainen V, Tryggvason K, Shaw AS, Miner JH. CD2AP is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere. Am J Physiol Renal Physiol (2000) 279:F785-92.
8. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science (2005) 308:1801-4. doi:10.1126/science.1106215
9. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet (2000) 24:251-6. doi:10.1038/73456
10. Goni FM, Alonso A. Effects of ceramide and other simple sphingolipids on membrane lateral structure. Biochim Biophys Acta (2009) 1788:169-77. doi:10.1016/j.bbamem.2008.09.002
11. van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J (2003) 369:199-211. doi:10.1042/BJ20021528
12. Zhang Y, Li X, Becker KA, Gulbins E. Ceramide-enriched membrane domains - structure and function. Biochim Biophys Acta (2009) 1788:178-83. doi:10.1016/j.bbamem.2008.07.030
13. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature (1993) 365:557-60. doi:10.1038/365557a0
14. Kaipia A, Chun SY, Eisenhauer K, Hsueh AJ. Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology (1996) 137:4864-70. doi:10.1210/endo.137.11.8895358
15. Merrill AH. Ceramide: a new lipid "second messenger"? Nutr Rev (1992) 50:78-80. doi:10.1111/j.1753-4887.1992.tb01273.x
16. Nagiec MM, Wells GB, Lester RL, Dickson RC. A suppressor gene that enables Saccharomyces cerevisiae to grow without making sphingolipids encodes a protein that resembles an Escherichia coli fatty acyltransferase. J Biol Chem (1993) 268:22156-63.
17. Merrill AH Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem (2002) 277:25843-6. doi:10.1074/jbc.R200009200
18. Mondal S, Mukhopadhyay C. Molecular level investigation of organization in ternary lipid bilayer: a computational approach. Langmuir (2008) 24:10298-305. doi:10.1021/la8015589
19. Hall A, Rog T, Karttunen M, Vattulainen I. Role of glycolipids in lipid rafts: a view through atomistic molecular dynamics simulations with galactosylceramide. J Phys Chem B (2010) 114:7797-807. doi:10.1021/jp912175d
20. Hakomori S. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J Biol Chem (1990) 265:18713-6.
21. Shayman JA, Radin NS. Structure and function of renal glycosphingolipids. Am J Physiol (1991) 260:F291-302.
22. Iwamori M, Shimomura J, Tsuyuhara S, Nagai Y. Gangliosides of various rat tissues: distribution of ganglio-N-tetraose-containing gangliosides and tissue-characteristic composition of gangliosides. J Biochem (1984) 95:761-70.
23. Saito M, Sugiyama K. Gangliosides in rat kidney: composition, distribution, and developmental changes. Arch Biochem Biophys (2001) 386:11-6. doi:10.1006/abbi.2000.2206
24. Hoon DS, Okun E, Neuwirth H, Morton DL, Irie RF. Aberrant expression of gangliosides in human renal cell carcinomas. J Urol (1993) 150:2013-8.
25. Reivinen J, Holthofer H, Miettinen A. A cell-type specific ganglioside of glomerular podocytes in rat kidney: an O-acetylated GD3. Kidney Int (1992) 42:624-31. doi:10.1038/ki.1992.327
26. Holthofer H, Reivinen J, Miettinen A. Nephron segment and cell-type specific expression of gangliosides in the developing and adult kidney. Kidney Int (1994) 45:123-30. doi:10.1038/ki.1994.14
27. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med (1991) 324:1464-70. doi:10.1056/NEJM199105233242104
28. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A (1990) 87:1913-6. doi:10.1073/pnas.87.5.1913
29. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med (2002) 113:112-9. doi:10.1016/S0002-9343(02)01150-6
30. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood (2010) 116:893-9. doi:10.1182/blood-2010-03-273151
31. Chander PN, Nurse HM, Pirani CL. Renal involvement in adult Gaucher's disease after splenectomy. Arch Pathol Lab Med (1979) 103:440-5.
32. Vaccaro AM, Motta M, Tatti M, Scarpa S, Masuelli L, Bhat M, et al. Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet (2010) 19:2987-97. doi:10.1093/hmg/ddq204
33. Sun Y, Witte DP, Zamzow M, Ran H, Quinn B, Matsuda J, et al. Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum Mol Genet (2007) 16:957-71. doi:10.1093/hmg/ddm040
34. Sandhoff K, Andreae U, Jatzkewitz H. Deficient hexozaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Life Sci (1968) 7:283-8. doi:10.1016/0024-3205(68)90024-6
35. Tatematsu M, Imaida K, Ito N, Togari H, Suzuki Y, Ogiu T. Sandhoff disease. Acta Pathol Jpn (1981) 31:503-12.
36. Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, Westphal H, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet (1995) 11:170-6. doi:10.1038/ng1095-170
37. Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, et al. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol (2006) 63:453-7. doi:10.1001/archneur.63.3.453
38. Krüger R, Bruns K, Grünhage S, Rossmann H, Reinke J, Beck M, et al. Determination of globotriaosylceramide in plasma and urine by mass spectrometry. Clin Chem Lab Med (2010) 48:189-98. doi:10.1515/CCLM.2010.048
39. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl (2005) 94:51-4; discussion 37-58. doi:10.1111/j.1651-2227.2005.tb02112.x
40. Gold H, Mirzaian M, Dekker N, Joao Ferraz M, Lugtenburg J, Codée JD, et al. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin Chem (2012) 59:547-56. doi:10.1373/clinchem.2012.192138
41. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta (2010) 411:1906-14. doi:10.1016/j.cca.2010.07.038
42. Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 451:823-34. doi:10.1007/s00428-007-0468-6
43. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol (2002) 13(Suppl 2):S134-8. doi:10.1097/01.ASN.0000016684.07368.75
44. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int (2002) 62:1933-46. doi:10.1046/j.1523-1755.2002.00675.x
45. Najafian B, Svarstad E, Bostad L, Gubler MC, Tøndel C, Whitley C, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int (2011) 79:663-70. doi:10.1038/ki.2010.484
46. Quinta R, Rodrigues D, Assunção M, Macedo MF, Azevedo O, Cunha D, et al. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy. Gene (2014) 536:97-104. doi:10.1016/j.gene.2013.11.073
47. Prabakaran T, Nielsen R, Larsen JV, Sørensen SS, Feldt-Rasmussen U, Saleem MA, et al. Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. PLoS One (2011) 6:e25065. doi:10.1371/journal.pone.0025065
48. Liebau MC, Braun F, Höpker K, Weitbrecht C, Bartels V, Müller RU, et al. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. PLoS One (2013) 8:e63506. doi:10.1371/journal.pone.0063506
49. Keppler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science (1999) 284:1372-6. doi:10.1126/science.284.5418.1372
50. Galeano B, Klootwijk R, Manoli I, Sun M, Ciccone C, Darvish D, et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest (2007) 117:1585-94. doi:10.1172/JCI30954
51. Ito M, Sugihara K, Asaka T, Toyama T, Yoshihara T, Furuichi K, et al. Glycoprotein hyposialylation gives rise to a nephrotic-like syndrome that is prevented by sialic acid administration in GNE V572L point-mutant mice. PLoS One (2012) 7:e29873. doi:10.1371/journal.pone.0029873
52. Samuelsson K, Zetterstrom R. Ceramides in a patient with lipogranulomatosis (Farber's disease) with chronic course. Scand J Clin Lab Invest (1971) 27:393-405. doi:10.3109/00365517109080235
53. Brière J, Calman F, Lageron A, Hinglais N, Emerit J, Bernard J. Adult Niemann-Pick disease: a 26 years follow-up. Report of a case with isolated visceral involvement, excess of tissue sphingomyelin, and deficient sphingomyelinase activity (author's transl). Nouv Rev Fr Hematol Blood Cells (1976) 16:185-202.
54. Kuemmel TA, Thiele J, Schroeder R, Stoffel W. Pathology of visceral organs and bone marrow in an acid sphingomyelinase deficient knock-out mouse line, mimicking human Niemann-Pick disease type A. A light and electron microscopic study. Pathol Res Pract (1997) 193:663-71. doi:10.1016/S0344-0338(97)80025-8
55. Miranda SR, He X, Simonaro CM, Gatt S, Dagan A, Desnick RJ, et al. Infusion of recombinant human acid sphingomyelinase into Niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J (2000) 14:1988-95. doi:10.1096/fj.00-0014com
56. Haltia A, Solin ML, Jalanko H, Holmberg C, Miettinen A, Holthöfer H. Sphingolipid activator proteins in a human hereditary renal disease with deposition of disialogangliosides. Histochem J (1996) 28:681-7. doi:10.1007/BF02409005
57. Tamaoki A, Kikkawa Y. The role of sulfatides in autoimmunity in children with various glomerular disease. Nihon Jinzo Gakkai Shi (1991) 33:1045-54.
58. Twfeek DM, Zaki SM. Role of tumour necrosis factor alpha and CD95 as markers of apoptosis in pathogenesis of pediatrics renal diseases. Egypt J Immunol (2005) 12:155-65.
59. De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, et al. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science (1997) 277:1652-5. doi:10.1126/science.277.5332.1652
60. De Maria R, Rippo MR, Schuchman EH, Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med (1998) 187:897-902. doi:10.1084/jem.187.6.897
61. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, et al. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med (1994) 180:1547-52. doi:10.1084/jem.180.4.1547
62. Omran OM, Saqr HE, Yates AJ. Molecular mechanisms of GD3-induced apoptosis in U-1242 MG glioma cells. Neurochem Res (2006) 31:1171-80. doi:10.1007/s11064-006-9147-2
63. Wiegmann K, Schwandner R, Krut O, Yeh WC, Mak TW, Krönke M. Requirement of FADD for tumor necrosis factor-induced activation of acid sphingomyelinase. J Biol Chem (1999) 274:5267-70. doi:10.1074/jbc.274.9.5267
64. Aguilar RP, Genta S, Sanchez S. Renal gangliosides are involved in lead intoxication. J Appl Toxicol (2008) 28:122-31. doi:10.1002/jat.1256
65. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia (1999) 42:1341-4. doi:10.1007/s001250051447
66. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int (2001) 59:2104-13. doi:10.1046/j.1523-1755.2001.0590062104.x
67. Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, et al. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int (2007) 72(10):1262-72. doi:10.1038/sj.ki.5002531
68. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 51:3083-9. doi:10.2337/diabetes.51.10.3083
69. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest (1997) 99:342-8. doi:10.1172/JCI119163
70. Kremer GJ, Atzpodien W, Schnellbacher E. Plasma glycosphingolipids in diabetics and normals. Klin Wochenschr (1975) 53:637-8. doi:10.1007/BF01469685
71. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes (2009) 58:337-43. doi:10.2337/db08-1228
72. Blachnio-Zabielska AU, Pulka M, Baranowski M, Nikolajuk A, Zabielski P, Górska M, et al. Ceramide metabolism is affected by obesity and diabetes in human adipose tissue. J Cell Physiol (2011) 227:550-7. doi:10.1002/jcp.22745
73. Gorska M, Dobrzyn A, Baranowski M. Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes. Med Sci Monit (2005) 11:CR35-8.
74. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett (2005) 579:1249-54. doi:10.1016/j.febslet.2004.12.094
75. Zador IZ, Deshmukh GD, Kunkel R, Johnson K, Radin NS, Shayman JA. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest (1993) 91:797-803. doi:10.1172/JCI116299
76. Kwak DH, Rho YI, Kwon OD, Ahan SH, Song JH, Choo YK, et al. Decreases of ganglioside GM3 in streptozotocin-induced diabetic glomeruli of rats. Life Sci (2003) 72:1997-2006. doi:10.1016/S0024-3205(03)00090-0
77. Liu G, Han F, Yang Y, Xie Y, Jiang H, Mao Y, et al. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin. Nephrol Dial Transplant (2011) 26:1493-502. doi:10.1093/ndt/gfq633
78. Yoo TH, Pedigo CE, Guzman J, Correa-Medina M, Wei C, Villarreal R, et al. SMPDL3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol (2014) 25(4):737-44. doi:10.1681/ASN.2013111213
79. Brunskill EW, Potter SS. Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy. BMC Nephrol (2012) 13:70. doi:10.1186/1471-2369-13-70
80. Ishizawa S, Takahashi-Fujigasaki J, Kanazawa Y, Matoba K, Kawanami D, Yokota T, et al. Sphingosine-1-phosphate induces differentiation of cultured renal tubular epithelial cells under Rho kinase activation via the S1P2 receptor. Clin Exp Nephrol (2014). doi:10.1007/s10157-014-0933-x
81. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes (2006) 55:2579-87. doi:10.2337/db06-0330
82. Holthofer H, Reivinen J, Solin ML, Haltia A, Miettinen A. Decrease of glomerular disialogangliosides in puromycin nephrosis of the rat. Am J Pathol (1996) 149:1009-15.
83. Andrews PM. Glomerular epithelial alterations resulting from sialic acid surface coat removal. Kidney Int (1979) 15:376-85. doi:10.1038/ki.1979.49
84. Pawluczyk IZ, Ghaderi Najafabadi M, Patel S, Desai P, Vashi D, Saleem MA, et al. Sialic acid attenuates puromycin aminonucleoside-induced desialylation and oxidative stress in human podocytes. Exp Cell Res (2013) 320:258-68. doi:10.1016/j.yexcr.2013.10.017
85. Barisoni L, Bruggeman LA, Mundel P, D'Agati VD, Klotman PE. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int (2000) 58:173-81. doi:10.1046/j.1523-1755.2000.00152.x
86. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest (1997) 100:84-92. doi:10.1172/JCI119525
87. Mikulak J, Singhal PC. HIV-1 entry into human podocytes is mediated through lipid rafts. Kidney Int (2010) 77:72-3; author reply 73-4. doi:10.1038/ki.2009.366
88. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, et al. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A (1992) 89:1577-81. doi:10.1073/pnas.89.5.1577
89. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol (2002) 13:1806-15. doi:10.1097/01.ASN.0000019642.55998.69
90. Kajiyama W, Kopp JB, Marinos NJ, Klotman PE, Dickie P. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int (2000) 58:1148-59. doi:10.1046/j.1523-1755.2000.00271.x
91. Sunamoto M, Husain M, He JC, Schwartz EJ, Klotman PE. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int (2003) 64:1695-701. doi:10.1046/j.1523-1755.2003.00283.x
92. Hanna Z, Priceputu E, Hu C, Vincent P, Jolicoeur P. HIV-1 Nef mutations abrogating downregulation of CD4 affect other Nef functions and show reduced pathogenicity in transgenic mice. Virology (2006) 346:40-52. doi:10.1016/j.virol.2005.10.010
93. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 22:2129-37. doi:10.1681/ASN.2011040388
94. Liu XH, Lingwood CA, Ray PE. Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease. Kidney Int (1999) 55:554-61. doi:10.1046/j.1523-1755.1999.00278.x
95. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis (2004) 44:815-25. doi:10.1053/j.ajkd.2004.07.008
96. Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant (2004) 8:329-33. doi:10.1111/j.1399-3046.2004.00181.x
97. Hubsch H, Montané B, Abitbol C, Chandar J, Shariatmadar S, Ciancio G, et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol (2005) 20:210-6. doi:10.1007/s00467-004-1706-7
98. Senggutuvan P, Cameron JS, Hartley RB, Rigden S, Chantler C, Haycock G, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol (1990) 4:21-8. doi:10.1007/BF00858431
99. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3:85ra46. doi:10.1126/scitranslmed.3002231
100. Tasaki M, Shimizu A, Hanekamp I, Torabi R, Villani V, Yamada K. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation. J Am Soc Nephrol (2014) 25:737-44. doi:10.1681/ASN.2013040363
101. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med (2008) 14:55-63. doi:10.1038/nm1696
102. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 23:2051-9. doi:10.1681/ASN.2012030302
103. Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aguillon-Prada R, Mendez A, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes (2013) 62(11):3817-27. doi:10.2337/db13-0399
104. Pyne NJ, Long JS, Lee SC, Loveridge C, Gillies L, Pyne S. New aspects of sphingosine 1-phosphate signaling in mammalian cells. Adv Enzyme Regul (2009) 49:214-21. doi:10.1016/j.advenzreg.2009.01.011
105. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol (2005) 5:560-70. doi:10.1038/nri1650
106. Imasawa T, Kitamura H, Ohkawa R, Satoh Y, Miyashita A, Yatomi Y. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp Toxicol Pathol (2010) 62:53-60. doi:10.1016/j.etp.2009.02.068
107. Koch A, Völzke A, Puff B, Blankenbach K, Meyer Zu Heringdorf D, Huwiler A, et al. PPARgamma agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells. Biochim Biophys Acta (2013) 1831:1634-43. doi:10.1016/j.bbalip.2013.07.011
108. Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int (2011) 79:1090-8. doi:10.1038/ki.2010.544
109. Park SW, Kim M, Chen SW, Brown KM, D'Agati VD, Lee HT. Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab Invest (2010) 90:1209-24. doi:10.1038/labinvest.2010.102
110. Kim M, Park SW, Pitson SM, Lee HT. Isoflurane protects human kidney proximal tubule cells against necrosis via sphingosine kinase and sphingosine-1-phosphate generation. Am J Nephrol (2010) 31:353-62. doi:10.1159/000298339
111. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol (2006) 290:F1516-24. doi:10.1152/ajprenal.00311.2005
112. Park SW, Kim M, D'Agati VD, Lee HT. Sphingosine kinase 1 protects against renal ischemia-reperfusion injury in mice by sphingosine-1-phosphate1 receptor activation. Kidney Int (2011) 80:1315-27. doi:10.1038/ki.2011.281
113. Zager RA, Conrad S, Lochhead K, Sweeney EA, Igarashi Y, Burkhart KM. Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure. Kidney Int (1998) 53:573-82. doi:10.1046/j.1523-1755.1998.00772.x
114. Kalhorn T, Zager RA. Renal cortical ceramide patterns during ischemic and toxic injury: assessments by HPLC-mass spectrometry. Am J Physiol (1999) 277:F723-33.
115. Zager RA, Iwata M, Conrad DS, Burkhart KM, Igarashi Y. Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int (1997) 52:60-70. doi:10.1038/ki.1997.304
116. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Krämer S, et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int (2004) 66:1434-43. doi:10.1111/j.1523-1755.2004.00906.x
117. Martini S, Krämer S, Loof T, Wang-Rosenke Y, Daig U, Budde K, et al. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am J Physiol Renal Physiol (2007) 292:F1761-70. doi:10.1152/ajprenal.00253.2006
118. Schwalm S, Pfeilschifter J, Huwiler A. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol (2014) 114:44-9. doi:10.1111/bcpt.12103
119. Ferguson R. FTY720 immunomodulation: optimism for improved transplant regimens. Transplant Proc (2004) 36:549S-53S. doi:10.1016/j.transproceed.2004.01.061
120. Fujishiro J, Kudou S, Iwai S, Takahashi M, Hakamata Y, Kinoshita M, et al. Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation (2006) 82:804-12. doi:10.1097/01.tp.0000232687.78242.cd
121. Watson L, Tullus K, Marks SD, Holt RC, Pilkington C, Beresford MW. Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus. J Clin Immunol (2012) 32:1019-25. doi:10.1007/s10875-012-9710-3
122. Snider AJ, Ruiz P, Obeid LM, Oates JC. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS One (2013) 8:e53521. doi:10.1371/journal.pone.0053521
123. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestilä M, Jalanko H, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A (1999) 96:7962-7. doi:10.1073/pnas.96.14.7962
124. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol (1999) 10:2440-5.
125. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol (2002) 13:630-8.
126. Smoyer WE, Mundel P. Regulation of podocyte structure during the development of nephrotic syndrome. J Mol Med (Berl) (1998) 76:172-83. doi:10.1007/s001090050206
127. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest (2001) 108:1583-7. doi:10.1172/JCI200114629
128. Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol (2003) 7:255-9. doi:10.1007/s10157-003-0259-6
129. Ichimura K, Kurihara H, Sakai T. Actin filament organization of foot processes in rat podocytes. J Histochem Cytochem (2003) 51:1589-600. doi:10.1177/002215540305101203
130. Ichimura K, Kurihara H, Sakai T. Actin filament organization of foot processes in vertebrate glomerular podocytes. Cell Tissue Res (2007) 329:541-57. doi:10.1007/s00441-007-0440-4
131. Yuan H, Takeuchi E, Salant DJ. Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. Am J Physiol Renal Physiol (2002) 282:F585-91. doi:10.1152/ajprenal.00290.2001
132. Huber TB, Simons M, Hartleben B, Sernetz L, Schmidts M, Gundlach E, et al. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet (2003) 12:3397-405. doi:10.1093/hmg/ddg360
133. Huber TB, Kottgen M, Schilling B, Walz G, Benzing T. Interaction with podocin facilitates nephrin signaling. J Biol Chem (2001) 276:41543-6. doi:10.1074/jbc.C100452200
134. Fanning AS, Ma TY, Anderson JM. Isolation and functional characterization of the actin binding region in the tight junction protein ZO-1. FASEB J (2002) 16:1835-7. doi:10.1096/fj.02-0121fje
135. Simons M, Schwarz K, Kriz W, Miettinen A, Reiser J, Mundel P, et al. Involvement of lipid rafts in nephrin phosphorylation and organization of the glomerular slit diaphragm. Am J Pathol (2001) 159:1069-77. doi:10.1016/S0002-9440(10)61782-8
136. Wang F, Nobes CD, Hall A, Spiegel S. Sphingosine 1-phosphate stimulates rho-mediated tyrosine phosphorylation of focal adhesion kinase and paxillin in Swiss 3T3 fibroblasts. Biochem J (1997) 324(Pt 2):481-8.
137. Shabahang S, Liu YH, Huwiler A, Pfeilschifter J. Identification of the LIM kinase-1 as a ceramide-regulated gene in renal mesangial cells. Biochem Biophys Res Commun (2002) 298:408-13. doi:10.1016/S0006-291X(02)02483-X
138. Takenouchi H, Kiyokawa N, Taguchi T, Matsui J, Katagiri YU, Okita H, et al. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J Cell Sci (2004) 117:3911-22. doi:10.1242/jcs.01246
139. Jin J, Sison K, Li C, Tian R, Wnuk M, Sung HK, et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 151:384-99. doi:10.1016/j.cell.2012.08.037